E-mails relating to Pfizer-BioNTech COVID-19 vaccine

Dear Medicines and Healthcare products Regulatory Agency (MHRA),

I am writing to make a request for information under section 1 of the Freedom of Information Act 2000.

Please can you provide me with copies of all e-mails sent or received by the head of the MHRA's Biologicals Unit since the start of the COVID-19 pandemic which contain at least one of the following words (spelled with any combination of upper- and lower-case letters):
- Pfizer
- BioNTech
- BNT162b2
- Tozinameran
- Comirnaty

NB: E-mails are not in and of themselves exempt information, though I accept that they may require to be redacted to remove any exempt information contained within them. On that note, it is worth drawing your attention to ICO guidance document "Requests where the cost of compliance exceeds the appropriate limit" (https://ico.org.uk/media/for-organisatio...), which states: "the staff time taken, or likely to be taken, in removing any exempt information in order to leave the information that is to be disclosed, often referred to as ‘redaction’, cannot be included as part of the costs of extracting the requested information".

Yours faithfully,

Kenneth MacArthur

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: Kenneth MacArthur
<[FOI #809595 email]> Sent: Saturday, November 20,
2021 8:07:48 PM To: MHRA Customer Services Subject: Freedom of Information
request - E-mails relating to Pfizer-BioNTech COVID-19 vaccine Dear
Medicines and Healthcare products Regulatory Agency (MHRA), I am writing
to make a request for information under section 1 of the Freedom of
Information Act 2000. Please can you provide me with copies of all e-mails
sent or received by the head of the MHRA's Biologicals Unit since the
start of the COVID-19 pandemic which contain at least one of the following
words (spelled with any combination of upper- and lower-case letters): -
Pfizer - BioNTech - BNT162b2 - Tozinameran - Comirnaty NB: E-mails are not
in and of themselves exempt information, though I accept that they may
require to be redacted to remove any exempt information contained within
them. On that note, it is worth drawing your attention to ICO guidance
document "Requests where the cost of compliance exceeds the appropriate
limit"
(https://eur01.safelinks.protection.outlo...),
which states: "the staff time taken, or likely to be taken, in removing
any exempt information in order to leave the information that is to be
disclosed, often referred to as ‘redaction’, cannot be included as part of
the costs of extracting the requested information". Yours faithfully,
Kenneth MacArthur
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #809595 email] Is [MHRA request email] the wrong
address for Freedom of Information requests to Medicines and Healthcare
Products Regulatory Agency? If so, please contact us using this form:
https://eur01.safelinks.protection.outlo...
Disclaimer: This message and any reply that you make will be published on
the internet. Our privacy and copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

1 Attachment

  • Attachment

    FOI 21 1243 CSC 76306 Freedom of Information request E mails relating to Novavax COVID 19 vaccine.txt

    4K Download View as HTML

Our Ref: FOI 21/1243

Dear Kenneth MacArthur,

RE: REQUEST UNDER THE FREEDOM OF INFORMATION ACT 2000

Thank you for your enquiry which we received on 22nd November 2021. Please note that as this and the attached are substantially similar requests they have been combined into one FOI request.

I confirm that your request is now being handled under the Freedom of Information Act and you should receive a reply within 20 working days from our date of receipt.

If you need to contact us again about this request, please quote the reference number above.

Please be aware that we publish FOIs replies and these are redacted and are located on our website at the following link below.
https://www.gov.uk/government/collection...

Kind Regards,

MHRA Customer Service Centre

Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 0203 080 6000

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

 

Dear Kenneth MacArthur,

 

Thank you for your emails which have been combined for one FOI response.

 

Your first request asked:

“Please can you provide me with copies of all e-mails sent or received by
the head of the MHRA's Biologicals Unit since the start of the COVID-19
pandemic which contain at least one of the following words (spelled with
any combination of upper- and lower-case letters):

- Novavax

- Covovax

- NVX-CoV2373

- Nuvaxovid”

 

Regarding your request for emails related to the terms Novavax, Covovax,
NVX-CoV2373 and Nuvaxovid, which are not currently authorised for use,
MHRA neither confirms nor denies that it holds information falling within
the description specified in your request. The duty in Section 1(1)(a) of
the Freedom of Information (FOI) Act 2000 does not apply, by virtue of
Section 41 (Information provided in confidence) and Section 43 (Commercial
interests) of that Act. This should not be taken as an indication that the
information you requested is or is not held by the department.

 

Section 41 is an absolute exemption and no consideration of the public
interest is required, except to state that we consider its disclosure to
constitute an actionable breach of confidence.

 

Section 43 is a qualified exemption and a consideration of the public
interest should be made. We have considered the public interest and cannot
see any public interest argument that outweighs the commercial harm in
alerting competitors to whether a rival product is trying to come onto the
market or not. Examples of public interest arguments would be a major
public health risk or a major procedural failure or irregularity.

 

Your second request asked:

“Please can you provide me with copies of all e-mails sent or received by
the head of the MHRA's Biologicals Unit since the start of the COVID-19
pandemic which contain at least one of the following words (spelled with
any combination of upper- and lower-case letters):

- Pfizer

- BioNTech

- BNT162b2

- Tozinameran

- Comirnaty”

 

I can confirm that the MHRA does hold some of the information that you
have requested. However, we have also determined that the information is
exempt under Section 12 of the Freedom of Information Act and we cannot
process your request any further.

 

Section 12 of the Act allows public authorities to refuse requests where
the cost of dealing with them would exceed the appropriate limit, which
for central government is set at £600. This represents the estimated cost
of one person spending 24 working hours in determining whether the
department holds the information, locating, retrieving and extracting the
information.

 

In order to process your request, we would need to: identify all emails
received which referenced the requested words in addition to identifying
any emails where these may have been misspelt. We consider that this would
take longer than 24 working hours to complete.

 

We advise that you narrow your request by, for example, reducing your
request to a single product and a single issue/point of interest about
that product.

 

Please note that substantially similar requests made within 60 working
days of an original request can be aggregated into one for the purposes of
calculating a cost limit, meaning that section 12 could still apply.

 

If you have a query about the information provided, please reply to this
email

 

If you disagree with how we have interpreted the Freedom of Information
Act 2000 in answering your request, you can ask for an internal review.
Please reply to this email, within two months of this reply, specifying
that you would like an Internal Review to be carried out.

 

Due to the ongoing Covid-19 situation, we are not able to accept delivery
of any documents or correspondence by post or courier to any of our
offices

 

Please remember to quote the reference number above in any future
communications.

 

If you were to remain dissatisfied with the outcome of the internal
review, you would have the right to apply directly to the Information
Commissioner for a decision. Please bear in mind that the Information
Commissioner will not normally review our handling of your request unless
you have first contacted us to conduct an internal review. The Information
Commissioner can be contacted at:

 

Information Commissioner’s Office

Wycliffe House

Water Lane

Wilmslow

Cheshire

SK9 5AF

 

Kind regards,

 

MHRA Customer Service Centre

 

Medicines and Healthcare products Regulatory Agency

10 South Colonnade, Canary Wharf, London E14 4PU

Telephone 020 3080 6000

 

 

 

 

show quoted sections

Kenneth MacArthur

Dear Medicines and Healthcare products Regulatory Agency (MHRA),

Please pass this on to the person who conducts Freedom of Information reviews.

I am writing to request an internal review of the MHRA's handling of my FOI request 'E-mails relating to Pfizer-BioNTech COVID-19 vaccine' (request A), which you combined with my FOI request 'E-mails relating to Novavax COVID-19 vaccine' (request B).

I would request that you respond to each sub-point ((i), (ii), etc) separately.

Regarding request B first:
(i) You have stated that the information requested is absolutely exempt under section 41 of the Freedom of Information Act (FOIA) 2000. However, per ICO guidance (https://ico.org.uk/media/for-organisatio...), this exemption does not cover "information the authority has generated itself" (paragraph 13), so would not, for example, include e-mails sent between MHRA staff or contractors, or consultants carrying out work on the MHRA's behalf. I would therefore invite you to withdraw your contention that section 41 covers every piece of information caught by this request.
(ii) You have stated that, following consideration of the public interest, the information requested is exempt under section 43 FOIA 2000, as releasing it would result in "commercial harm in alerting competitors to whether a rival product is trying to come onto the market or not". This contention is unfortunately spurious, as Novavax itself has already alerted competitors to this fact in its press release of 27 October 2021 (https://ir.novavax.com/2021-10-27-Novava...), and in subsequent media appearances by its CEO. I would therefore invite you to withdraw your contention that section 43 is relevant here, at least in so far as it relates to alerting Novavax's competitors that their COVID-19 vaccine is trying to come onto the GB market.
(iii) Further, the licensing process, particularly one involving conditional authorisation, is not a black and white one, whereby a vaccine is licensed for a single, immutable indication, with a known suite of side effects, with the regulator never considering the topic again. There are presumably numerous kinds of information relating to a particular vaccine that could impact the commercial interests of the license holder - eg, on significant side effects, on material changes to the product information leaflet, on requested changes/additions to the indication, and so on - yet the MHRA routinely relies on this exemption - or at least considers that the public interest is against release of the requested information - only when asked about as-yet-unauthorised vaccines. Why? Why do you elevate alerting competitors about a new product trying to come onto the market - significantly, even when applicants have already publicly disclosed this fact themselves - above many other matters that would also impact a license holder's commercial interests? Do you agree that this is an inconsistent use of section 43?
(iv) Finally on request B, I would ask you to reconsider my request in light of the previous three points.

And regarding request A:
(v) You have stated that, in order to process my request, you would need to "identify all emails received which referenced the requested words in addition to identifying any emails where these may have been misspelt". I have not asked you to identify e-mails where these words may have been misspelt, and I am hereby explicitly confirming that I do not wish you to do this. Can you confirm that that part of your basis for relying on section 12 FOIA 2000 has now fallen away?
(vi) Given the previous point, you simply need to identify all e-mails sent or received by a single person containing the specified words. It is not clear to me why identifying those e-mails should take anywhere near 24 hours to complete. I would ask you to provide cogent evidence for this estimate, per paragraph 37 of the ICO guidance document on section 12 (https://ico.org.uk/media/for-organisatio...), noting that, while doing so is not a statutory requirement, it will allow me to assess the reasonableness of the estimate, and be required in any case if a complaint is made to the Information Commissioner (per paragraph 38 of the ICO guidance document).
(vii) You have suggested that I narrow my request "by, for example, reducing [my] request to a single product and a single issue/point of interest about that product". This request _is_ for a single product, so can you please explain why you have suggested this? Did this part of your response come from some sort of generic FOI response, included without cognizance being taken of the specifics of the request at hand?
(viii) Further, can you please explain how narrowing my request to cover a single issue/point of interest about the Pfizer-BioNTech COVID-19 vaccine will make it easier for you to comply with my request? Surely devising a search strategy to identify e-mails which are about both (a) the Pfizer-BioNTech COVID-19 vaccine, and (b) specific issues/points of interest about that vaccine, will be more complicated than simply identifying all e-mails about that vaccine. If you don't believe this to be the case, can you please explain why, noting that per paragraph 15 of the aforementioned ICO guidance document, "the staff time taken, or likely to be taken, in removing any exempt information in order to leave the information that is to be disclosed, often referred to as ‘redaction’, cannot be included as part of the costs of extracting the requested information".
(ix) Finally on request A, I would ask you to reconsider my request in light of the previous four points.

A full history of my FOI request and all correspondence is available on the Internet at this address: https://www.whatdotheyknow.com/request/e...

Yours faithfully,

Kenneth MacArthur

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: Kenneth MacArthur
<[FOI #809595 email]> Sent: Saturday, January 15,
2022 6:50:22 PM To: MHRA Customer Services Subject: Internal review of
Freedom of Information request - E-mails relating to Pfizer-BioNTech
COVID-19 vaccine Dear Medicines and Healthcare products Regulatory Agency
(MHRA), Please pass this on to the person who conducts Freedom of
Information reviews. I am writing to request an internal review of the
MHRA's handling of my FOI request 'E-mails relating to Pfizer-BioNTech
COVID-19 vaccine' (request A), which you combined with my FOI request
'E-mails relating to Novavax COVID-19 vaccine' (request B). I would
request that you respond to each sub-point ((i), (ii), etc) separately.
Regarding request B first: (i) You have stated that the information
requested is absolutely exempt under section 41 of the Freedom of
Information Act (FOIA) 2000. However, per ICO guidance
(https://eur01.safelinks.protection.outlo...),
this exemption does not cover "information the authority has generated
itself" (paragraph 13), so would not, for example, include e-mails sent
between MHRA staff or contractors, or consultants carrying out work on the
MHRA's behalf. I would therefore invite you to withdraw your contention
that section 41 covers every piece of information caught by this request.
(ii) You have stated that, following consideration of the public interest,
the information requested is exempt under section 43 FOIA 2000, as
releasing it would result in "commercial harm in alerting competitors to
whether a rival product is trying to come onto the market or not". This
contention is unfortunately spurious, as Novavax itself has already
alerted competitors to this fact in its press release of 27 October 2021
(https://eur01.safelinks.protection.outlo...),
and in subsequent media appearances by its CEO. I would therefore invite
you to withdraw your contention that section 43 is relevant here, at least
in so far as it relates to alerting Novavax's competitors that their
COVID-19 vaccine is trying to come onto the GB market. (iii) Further, the
licensing process, particularly one involving conditional authorisation,
is not a black and white one, whereby a vaccine is licensed for a single,
immutable indication, with a known suite of side effects, with the
regulator never considering the topic again. There are presumably numerous
kinds of information relating to a particular vaccine that could impact
the commercial interests of the license holder - eg, on significant side
effects, on material changes to the product information leaflet, on
requested changes/additions to the indication, and so on - yet the MHRA
routinely relies on this exemption - or at least considers that the public
interest is against release of the requested information - only when asked
about as-yet-unauthorised vaccines. Why? Why do you elevate alerting
competitors about a new product trying to come onto the market -
significantly, even when applicants have already publicly disclosed this
fact themselves - above many other matters that would also impact a
license holder's commercial interests? Do you agree that this is an
inconsistent use of section 43? (iv) Finally on request B, I would ask you
to reconsider my request in light of the previous three points. And
regarding request A: (v) You have stated that, in order to process my
request, you would need to "identify all emails received which referenced
the requested words in addition to identifying any emails where these may
have been misspelt". I have not asked you to identify e-mails where these
words may have been misspelt, and I am hereby explicitly confirming that I
do not wish you to do this. Can you confirm that that part of your basis
for relying on section 12 FOIA 2000 has now fallen away? (vi) Given the
previous point, you simply need to identify all e-mails sent or received
by a single person containing the specified words. It is not clear to me
why identifying those e-mails should take anywhere near 24 hours to
complete. I would ask you to provide cogent evidence for this estimate,
per paragraph 37 of the ICO guidance document on section 12
(https://eur01.safelinks.protection.outlo...),
noting that, while doing so is not a statutory requirement, it will allow
me to assess the reasonableness of the estimate, and be required in any
case if a complaint is made to the Information Commissioner (per paragraph
38 of the ICO guidance document). (vii) You have suggested that I narrow
my request "by, for example, reducing [my] request to a single product and
a single issue/point of interest about that product". This request _is_
for a single product, so can you please explain why you have suggested
this? Did this part of your response come from some sort of generic FOI
response, included without cognizance being taken of the specifics of the
request at hand? (viii) Further, can you please explain how narrowing my
request to cover a single issue/point of interest about the
Pfizer-BioNTech COVID-19 vaccine will make it easier for you to comply
with my request? Surely devising a search strategy to identify e-mails
which are about both (a) the Pfizer-BioNTech COVID-19 vaccine, and (b)
specific issues/points of interest about that vaccine, will be more
complicated than simply identifying all e-mails about that vaccine. If you
don't believe this to be the case, can you please explain why, noting that
per paragraph 15 of the aforementioned ICO guidance document, "the staff
time taken, or likely to be taken, in removing any exempt information in
order to leave the information that is to be disclosed, often referred to
as ‘redaction’, cannot be included as part of the costs of extracting the
requested information". (ix) Finally on request A, I would ask you to
reconsider my request in light of the previous four points. A full history
of my FOI request and all correspondence is available on the Internet at
this address:
https://eur01.safelinks.protection.outlo...
Yours faithfully, Kenneth MacArthur
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #809595 email] Disclaimer: This message and
any reply that you make will be published on the internet. Our privacy and
copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Internal Review of FOI 22/1243

Dear Kenneth MacArthur,

Thank you for your email.

We confirm that an internal review will be carried out on FOI 22/1243. We normally aim to respond to requests for internal review within 20 working days of receipt. However, due to high volumes of queries we are currently receiving related to COVID-19 please be aware that responses may take longer than usual.  

Kind Regards  

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Dear Kenneth MacArthur,
 
Thank you for your email.
 
Your internal review is currently in hand and we will respond to you once
the review has been completed.
 
Kind Regards
 
 
MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf,
London E14 4PU
Telephone 020 3080 6000
 
 

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Dear Kenneth MacArthur,

Thank you for your email.

We wanted to update you that your request is in hand and we acknowledge that it is complex however the team will endeavour to provide you with a response.

We apologise for any inconvenience caused.

Kind Regards

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU Telephone 020 3080 6000

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Dear Kenneth MacArthur,

Thank you for your email.

We have noted that elements of this request are complex, and therefore, additional time will be necessary in order to conduct a thorough review.

We apologise for any inconvenience caused.

Kind Regards

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU Telephone 020 3080 6000

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

MHRA Customer Services would like to recall the message, "Internal Review of FOI 22/1243 - RE: Internal review of Freedom of Information request - E-mails relating to Pfizer-BioNTech COVID-19 vaccine".
DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click DHTermsAndConditions<https://www.gov.uk/help/terms-conditions>

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

MHRA Customer Services would like to recall the message, "Internal Review of FOI 22/1243 - RE: Internal review of Freedom of Information request - E-mails relating to Pfizer-BioNTech COVID-19 vaccine".
DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click DHTermsAndConditions<https://www.gov.uk/help/terms-conditions>

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Dear Kenneth MacArthur,

Thank you for your email.

We wanted to update you to mention that your request is in hand, and also to inform you that have noted that elements of this request are complex, and therefore, additional time will be necessary in order to conduct a thorough internal review.

We apologise for any inconvenience caused.

Kind Regards

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU Telephone 020 3080 6000

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Dear Mr Kenneth MacArthur,

We have been conducting a more detailed sampling exercise in relation to your FOI request and subsequent request for internal review. The exercise has already identified over 1200 emails and there are still two more email catalogue files yet to be searched—we expect these searches will return similar numbers of emails when using the search terms specified in your request.

Therefore, due to the thousands of emails expected to be subject to this request / internal review, we are writing to you to ask if there is a particular form / piece of information that you are seeking, that may help us to refine the search and offer a better outcome for you in terms of the internal review.

Kind Regards

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU Telephone 020 3080 6000

show quoted sections

Kenneth MacArthur

Dear Medicines and Healthcare products Regulatory Agency (MHRA),

Thank you for your e-mail.

You ask "if there is a particular form / piece of information that [I am] seeking".

My concern here is that complicating the search with additional parameters will mean it takes longer to complete. One or two thousand e-mails may result in a large PDF, but I am happy to go through that in my own time rather than taking up any more of your time doing so.

Yours faithfully,

Kenneth MacArthur

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: Kenneth MacArthur
<[FOI #809595 email]> Sent: Monday, March 28, 2022
11:07:15 AM To: MHRA Customer Services Subject: Re: Internal Review of FOI
22/1243 - RE: Internal review of Freedom of Information request - E-mails
relating to Pfizer-BioNTech COVID-19 vaccine Dear Medicines and Healthcare
products Regulatory Agency (MHRA), Thank you for your e-mail. You ask "if
there is a particular form / piece of information that [I am] seeking". My
concern here is that complicating the search with additional parameters
will mean it takes longer to complete. One or two thousand e-mails may
result in a large PDF, but I am happy to go through that in my own time
rather than taking up any more of your time doing so. Yours faithfully,
Kenneth MacArthur -----Original Message----- Dear Mr Kenneth MacArthur, We
have been conducting a more detailed sampling exercise in relation to your
FOI request and subsequent request for internal review. The exercise has
already identified over 1200 emails and there are still two more email
catalogue files yet to be searched—we expect these searches will return
similar numbers of emails when using the search terms specified in your
request. Therefore, due to the thousands of emails expected to be subject
to this request / internal review, we are writing to you to ask if there
is a particular form / piece of information that you are seeking, that may
help us to refine the search and offer a better outcome for you in terms
of the internal review. Kind Regards MHRA Customer Experience Centre
Communications and engagement team Medicines and Healthcare products
Regulatory Agency 10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #809595 email] Disclaimer: This message and
any reply that you make will be published on the internet. Our privacy and
copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Dear Mr MacArthur,

Thank you for your email.

Please note that the MHRA has a responsibility to check all information before we release, in order to ascertain whether the information is relevant to your request. This is why we have a stipulation under Section 12 of the FOI Act that allows us to refuse a request that is too large and request refinement.

Kind Regards

MHRA Customer Experience Centre

Communications and engagement team

Medicines and Healthcare products Regulatory Agency

10 South Colonnade, Canary Wharf, London E14 4PU Telephone 020 3080 6000

show quoted sections

Kenneth MacArthur

Dear Medicines and Healthcare products Regulatory Agency,

Thank you for your e-mail of 11 April 2022.

It is not clear to me, however, whether there is a question in your e-mail which I need to respond to.

Can you confirm whether there is a question which I need to respond to.

If there is a question which I need to respond to, can you:
(a) Express the question clearly in the form of a question.
(b) Confirm what will happen to my FOI request if I do not respond to the question.
(c) Explain what the rationale is for (b).

Thank you in advance for providing that clarity.

Yours faithfully,

Kenneth MacArthur

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: Kenneth MacArthur
<[FOI #809595 email]> Sent: Monday, April 11, 2022
3:26:27 PM To: MHRA Customer Services Subject: Re: Internal Review of FOI
22/1243 - RE: Internal review of Freedom of Information request - E-mails
relating to Pfizer-BioNTech COVID-19 vaccine Dear Medicines and Healthcare
products Regulatory Agency, Thank you for your e-mail of 11 April 2022. It
is not clear to me, however, whether there is a question in your e-mail
which I need to respond to. Can you confirm whether there is a question
which I need to respond to. If there is a question which I need to respond
to, can you: (a) Express the question clearly in the form of a question.
(b) Confirm what will happen to my FOI request if I do not respond to the
question. (c) Explain what the rationale is for (b). Thank you in advance
for providing that clarity. Yours faithfully, Kenneth MacArthur
-----Original Message----- Dear Mr MacArthur, Thank you for your email.
Please note that the MHRA has a responsibility to check all information
before we release, in order to ascertain whether the information is
relevant to your request. This is why we have a stipulation under Section
12 of the FOI Act that allows us to refuse a request that is too large and
request refinement. Kind Regards MHRA Customer Experience Centre
Communications and engagement team Medicines and Healthcare products
Regulatory Agency 10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #809595 email] Disclaimer: This message and
any reply that you make will be published on the internet. Our privacy and
copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: Kenneth MacArthur
<[FOI #809595 email]> Sent: Monday, April 11, 2022
3:26:27 PM To: MHRA Customer Services Subject: Re: Internal Review of FOI
22/1243 - RE: Internal review of Freedom of Information request - E-mails
relating to Pfizer-BioNTech COVID-19 vaccine Dear Medicines and Healthcare
products Regulatory Agency, Thank you for your e-mail of 11 April 2022. It
is not clear to me, however, whether there is a question in your e-mail
which I need to respond to. Can you confirm whether there is a question
which I need to respond to. If there is a question which I need to respond
to, can you: (a) Express the question clearly in the form of a question.
(b) Confirm what will happen to my FOI request if I do not respond to the
question. (c) Explain what the rationale is for (b). Thank you in advance
for providing that clarity. Yours faithfully, Kenneth MacArthur
-----Original Message----- Dear Mr MacArthur, Thank you for your email.
Please note that the MHRA has a responsibility to check all information
before we release, in order to ascertain whether the information is
relevant to your request. This is why we have a stipulation under Section
12 of the FOI Act that allows us to refuse a request that is too large and
request refinement. Kind Regards MHRA Customer Experience Centre
Communications and engagement team Medicines and Healthcare products
Regulatory Agency 10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #809595 email] Disclaimer: This message and
any reply that you make will be published on the internet. Our privacy and
copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

Kenneth MacArthur

Dear Medicines and Healthcare products Regulatory Agency,

Please can you reply to my e-mail requesting clarification of 11 April 2022.

Thanking you in advance.

Yours faithfully,

Kenneth MacArthur

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: Kenneth MacArthur
<[FOI #809595 email]> Sent: Tuesday, April 19, 2022
9:02:37 PM To: MHRA Customer Services Subject: RE: Internal Review of FOI
22/1243 - RE: Internal review of Freedom of Information request - E-mails
relating to Pfizer-BioNTech COVID-19 vaccine Dear Medicines and Healthcare
products Regulatory Agency, Please can you reply to my e-mail requesting
clarification of 11 April 2022. Thanking you in advance. Yours faithfully,
Kenneth MacArthur -----Original Message----- Thank you for your email.
This auto-response is to inform you that your email has been received and
will be reviewed by our Customer Service Team. We will respond to you as
soon as possible. Please note that we may not respond if your query: •
contains offensive language • has already been answered in a previous
reply to you • is illegible • is selling or promoting a product • is for
information only Medicines and Healthcare products Regulatory Agency 10
South Colonnade, Canary Wharf, London E14 4PU gov.uk/mhra Stay connected
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. The UK has left the EU, and the transition period ends on
31 December 2020. Ourguidance and information can be accessed here.
________________________________________ From: Kenneth MacArthur <[FOI
#809595 email]> Sent: Monday, April 11, 2022 3:26:27 PM To: MHRA Customer
Services Subject: Re: Internal Review of FOI 22/1243 - RE: Internal review
of Freedom of Information request - E-mails relating to Pfizer-BioNTech
COVID-19 vaccine Dear Medicines and Healthcare products Regulatory Agency,
Thank you for your e-mail of 11 April 2022. It is not clear to me,
however, whether there is a question in your e-mail which I need to
respond to. Can you confirm whether there is a question which I need to
respond to. If there is a question which I need to respond to, can you:
(a) Express the question clearly in the form of a question. (b) Confirm
what will happen to my FOI request if I do not respond to the question.
(c) Explain what the rationale is for (b). Thank you in advance for
providing that clarity. Yours faithfully, Kenneth MacArthur -----Original
Message----- Dear Mr MacArthur, Thank you for your email. Please note that
the MHRA has a responsibility to check all information before we release,
in order to ascertain whether the information is relevant to your request.
This is why we have a stipulation under Section 12 of the FOI Act that
allows us to refuse a request that is too large and request refinement.
Kind Regards MHRA Customer Experience Centre Communications and engagement
team Medicines and Healthcare products Regulatory Agency 10 South
Colonnade, Canary Wharf, London E14 4PU Telephone 020 3080 6000
------------------------------------------------------------------- Please
use this email address for all replies to this request: [FOI #809595
email] Disclaimer: This message and any reply that you make will be
published on the internet. Our privacy and copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #809595 email] Disclaimer: This message and
any reply that you make will be published on the internet. Our privacy and
copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: Kenneth MacArthur
<[FOI #809595 email]> Sent: Monday, April 11, 2022
3:26:27 PM To: MHRA Customer Services Subject: Followed up with FOI LD -
Re: Internal Review of FOI 22/1243 - RE: Internal review of Freedom of
Information request - E-mails relating to Pfizer-BioNTech COVID-19 vaccine
Dear Medicines and Healthcare products Regulatory Agency, Thank you for
your e-mail of 11 April 2022. It is not clear to me, however, whether
there is a question in your e-mail which I need to respond to. Can you
confirm whether there is a question which I need to respond to. If there
is a question which I need to respond to, can you: (a) Express the
question clearly in the form of a question. (b) Confirm what will happen
to my FOI request if I do not respond to the question. (c) Explain what
the rationale is for (b). Thank you in advance for providing that clarity.
Yours faithfully, Kenneth MacArthur -----Original Message----- Dear Mr
MacArthur, Thank you for your email. Please note that the MHRA has a
responsibility to check all information before we release, in order to
ascertain whether the information is relevant to your request. This is why
we have a stipulation under Section 12 of the FOI Act that allows us to
refuse a request that is too large and request refinement. Kind Regards
MHRA Customer Experience Centre Communications and engagement team
Medicines and Healthcare products Regulatory Agency 10 South Colonnade,
Canary Wharf, London E14 4PU Telephone 020 3080 6000
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #809595 email] Disclaimer: This message and
any reply that you make will be published on the internet. Our privacy and
copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

Kenneth MacArthur

Dear Medicines and Healthcare products Regulatory Agency,

Thank you for the further automatic response.

However, please could you reply to my clarification-requesting e-mail of 11 April 2022.

If it is easier than a further e-mail exchange, I am happy to have a phone call (or Zoom call) to discuss this further.

Please respond forthwith.

Yours faithfully,

Kenneth MacArthur

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: Kenneth MacArthur
<[FOI #809595 email]> Sent: Wednesday, May 4, 2022
8:39:24 AM To: MHRA Customer Services Subject: RE: Followed up with FOI LD
- Re: Internal Review of FOI 22/1243 - RE: Internal review of Freedom of
Information request - E-mails relating to Pfizer-BioNTech COVID-19 vaccine
Dear Medicines and Healthcare products Regulatory Agency, Thank you for
the further automatic response. However, please could you reply to my
clarification-requesting e-mail of 11 April 2022. If it is easier than a
further e-mail exchange, I am happy to have a phone call (or Zoom call) to
discuss this further. Please respond forthwith. Yours faithfully, Kenneth
MacArthur -----Original Message----- Thank you for your email. This
auto-response is to inform you that your email has been received and will
be reviewed by our Customer Service Team. We will respond to you as soon
as possible. Please note that we may not respond if your query: • contains
offensive language • has already been answered in a previous reply to you
• is illegible • is selling or promoting a product • is for information
only Medicines and Healthcare products Regulatory Agency 10 South
Colonnade, Canary Wharf, London E14 4PU gov.uk/mhra Stay connected For
information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. The UK has left the EU, and the transition period ends on
31 December 2020. Ourguidance and information can be accessed here.
________________________________________ From: Kenneth MacArthur <[FOI
#809595 email]> Sent: Monday, April 11, 2022 3:26:27 PM To: MHRA Customer
Services Subject: Followed up with FOI LD - Re: Internal Review of FOI
22/1243 - RE: Internal review of Freedom of Information request - E-mails
relating to Pfizer-BioNTech COVID-19 vaccine Dear Medicines and Healthcare
products Regulatory Agency, Thank you for your e-mail of 11 April 2022. It
is not clear to me, however, whether there is a question in your e-mail
which I need to respond to. Can you confirm whether there is a question
which I need to respond to. If there is a question which I need to respond
to, can you: (a) Express the question clearly in the form of a question.
(b) Confirm what will happen to my FOI request if I do not respond to the
question. (c) Explain what the rationale is for (b). Thank you in advance
for providing that clarity. Yours faithfully, Kenneth MacArthur
-----Original Message----- Dear Mr MacArthur, Thank you for your email.
Please note that the MHRA has a responsibility to check all information
before we release, in order to ascertain whether the information is
relevant to your request. This is why we have a stipulation under Section
12 of the FOI Act that allows us to refuse a request that is too large and
request refinement. Kind Regards MHRA Customer Experience Centre
Communications and engagement team Medicines and Healthcare products
Regulatory Agency 10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000
------------------------------------------------------------------- Please
use this email address for all replies to this request: [FOI #809595
email] Disclaimer: This message and any reply that you make will be
published on the internet. Our privacy and copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #809595 email] Disclaimer: This message and
any reply that you make will be published on the internet. Our privacy and
copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Dear Mr MacArthur,

 

This is a courtesy message to let you know that we are in the final stages
of signing off the internal review--we expect to be able to provide the
response by Friday 20^th May.

 

Sincere apologies for the delay encountered whilst we undertook this
review.

 

Kind regards,

 

 

MHRA Customer Experience Centre

Communications and engagement team

Medicines and Healthcare products Regulatory Agency

10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000

 

show quoted sections

Carrie Janssen left an annotation ()

It will be interesting to see what excuse they use so as not to provide you with the information you have requested.

Kenneth MacArthur

Dear Medicines and Healthcare products Regulatory Agency,

Thank you for your e-mail of 13 May 2022 confirming that you expected to be able to provide a response to my internal review request by 20 May 2022.

However, it is now 26 May 2022 and I still have not received that response.

Can you please confirm what has happened and what the new ETA is.

Yours faithfully,

Kenneth MacArthur

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

Thank you for your email.  This auto-response is to inform you that your
email has been received and will be reviewed by our Customer Service Team.
We will respond to you as soon as possible. 
 
Please note that we may not respond if your query: 
 
• contains offensive language
• has already been answered in a previous reply to you
• is illegible
• is selling or promoting a product
• is for information only 
 
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, 
Canary Wharf, 
London 
E14 4PU
gov.uk/mhra
Stay connected 
 
For information on how the Agency uses your personal data and your data
protection rights, please see our three centres’ Privacy Notices: MHRA,
CPRD and NIBSC. 
 
The UK has left the EU, and the transition period ends on 31 December
2020. Ourguidance and information can be accessed here.

________________________________________ From: Kenneth MacArthur
<[FOI #809595 email]> Sent: Thursday, May 26, 2022
12:15:31 PM To: MHRA Customer Services Subject: RE: Internal Review of FOI
22/1243 - RE: Internal review of Freedom of Information request - E-mails
relating to Pfizer-BioNTech COVID-19 vaccine Dear Medicines and Healthcare
products Regulatory Agency, Thank you for your e-mail of 13 May 2022
confirming that you expected to be able to provide a response to my
internal review request by 20 May 2022. However, it is now 26 May 2022 and
I still have not received that response. Can you please confirm what has
happened and what the new ETA is. Yours faithfully, Kenneth MacArthur
-----Original Message----- Dear Mr MacArthur, This is a courtesy message
to let you know that we are in the final stages of signing off the
internal review--we expect to be able to provide the response by Friday
20^th May. Sincere apologies for the delay encountered whilst we undertook
this review. Kind regards, MHRA Customer Experience Centre Communications
and engagement team Medicines and Healthcare products Regulatory Agency 10
South Colonnade, Canary Wharf, London E14 4PU Telephone 020 3080 6000
------------------------------------------------------------------- Please
use this email address for all replies to this request:
[FOI #809595 email] Disclaimer: This message and
any reply that you make will be published on the internet. Our privacy and
copyright policies:
https://eur01.safelinks.protection.outlo...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
https://eur01.safelinks.protection.outlo...
https://eur01.safelinks.protection.outlo...
Please note that in some cases publication of requests and responses will
be delayed. If you find this service useful as an FOI officer, please ask
your web manager to link to us from your organisation's FOI page.

show quoted sections

MHRA Customer Services, Medicines and Healthcare Products Regulatory Agency

1 Attachment

Dear Mr MacArthur,

 

Thank you for your email.

 

Please attached the reply to your Internal review.

 

Kind Regards

 

 

 

MHRA Customer Experience Centre

Communications and engagement team

Medicines and Healthcare products Regulatory Agency

10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000

 

 

 

show quoted sections